Giuseppe Pantaleo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8929064/publications.pdf

Version: 2024-02-01

161 papers	15,344 citations	38660 50 h-index	18606 119 g-index
174 all docs	174 docs citations	174 times ranked	14181 citing authors

#	Article	IF	Citations
1	High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. Clinical Microbiology and Infection, 2022, 28, 611.e1-611.e7.	2.8	3
2	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. JAMA Oncology, 2022, 8, e220446.	3.4	48
3	Human macrophages and monocyte-derived dendritic cells stimulate the proliferation of endothelial cells through midkine production. PLoS ONE, 2022, 17, e0267662.	1.1	4
4	Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. Viruses, 2022, 14, 1089.	1.5	9
5	Antibodies to combat viral infections: development strategies and progress. Nature Reviews Drug Discovery, 2022, 21, 676-696.	21.5	68
6	Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. Journal of Virology, 2021, 95, .	1.5	200
7	Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland. Open Forum Infectious Diseases, 2021, 8, ofab149.	0.4	18
8	Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	11
9	A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial. Journal of Virology, 2021, 95, .	1.5	6
10	Implementing SARS-CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: The INCREASE Study. Microorganisms, 2021, 9, 798.	1.6	51
11	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. Npj Vaccines, 2021, 6, 56.	2.9	7
12	Case Report: SARS-CoV-2 as an unexpected causal agent of isolated febrile hepatitis. F1000Research, 2021, 10, 400.	0.8	1
13	Case Report: A Rare Truncating Variant of the CFHR5 Gene in IgA Nephropathy. Frontiers in Genetics, 2021, 12, 529236.	1.1	3
14	Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	34
15	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. BMJ Open, 2021, 11, e049232.	0.8	10
16	Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports. Frontiers in Medicine, 2021, 8, 663258.	1.2	2
17	A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Science Translational Medicine, 2021, 13, .	5.8	68
18	The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nature Communications, 2021, 12, 4888.	5.8	67

#	Article	IF	Citations
19	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nature Communications, 2021, 12, 5215.	5.8	22
20	A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Reports, 2021, 37, 109814.	2.9	39
21	Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatology, The, 2021, 3, e617.	2.2	54
22	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. PLoS Pathogens, 2021, 17, e1010016.	2.1	1
23	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. Clinical Infectious Diseases, 2020, 72, 50-60.	2.9	15
24	The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet, The, 2020, 395, 384-388.	6.3	44
25	Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA. Viruses, 2020, 12, 973.	1.5	8
26	Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. PLoS Pathogens, 2020, 16, e1008522.	2.1	11
27	In Situ Characterization of Follicular Helper CD4 T Cells Using Multiplexed Imaging. Frontiers in Immunology, 2020, 11, 607626.	2.2	12
28	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Medicine, 2020, 17, e1003117.	3.9	8
29	TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice. PLoS Pathogens, 2020, 16, e1009025.	2.1	19
30	Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement. PLoS Pathogens, 2019, 15, e1007918.	2.1	16
31	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV,the, 2019, 6, e334-e340.	2.1	5
32	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. BMC Biotechnology, 2019, 19, 67.	1.7	15
33	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. Cell Host and Microbe, 2019, 26, 623-637.e8.	5.1	56
34	Safety and tolerance of lymph node biopsies from chronic HIV-1 volunteers in rural Tanzania. BMC Research Notes, 2019, 12, 561.	0.6	0
35	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e737-e749.	2.1	43
36	Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption. PLoS ONE, 2019, 14, e0210965.	1.1	8

#	Article	IF	Citations
37	Tumor suppression of novel antiâ€“PD-1 antibodies mediated through CD28 costimulatory pathway. Journal of Experimental Medicine, 2019, 216, 1525-1541.	4.2	23
38	SAT0205â€…A CYTOKINE â€œSCAR SIGNATUREâ€•CHARACTERIZES PATIENTS WITH FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND SJOGRENâ€™S SYNDROME. , 2019, , .		0
39	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Science Translational Medicine, 2019, 11, .	5.8	18
40	A Robust Method for Assaying the Immunoreactive Fraction in Nonequilibrium Systems. Pharmaceuticals, 2019, 12, 177.	1.7	8
41	Tâ€cell exhaustion in HIV infection. Immunological Reviews, 2019, 292, 149-163.	2.8	217
42	Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. Frontiers in Immunology, 2019, 10, 2941.	2.2	9
43	Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. PLoS ONE, 2019, 14, e0225622.	1.1	20
44	Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Antisense Protein (ASP) RNA Transcripts in Patients by Strand-Specific RT-PCR. Journal of Visualized Experiments, 2019, , .	0.2	3
45	HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. Journal of Virology, 2019, 93, .	1.5	48
46	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. Journal of Virology, 2019, 93, .	1.5	25
47	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. Journal of Virology, 2019, 93, .	1.5	13
48	Comparative analysis and generation of a robust HIV-1 DNA quantification assay. Journal of Virological Methods, 2019, 263, 24-31.	1.0	9
49	Detection of antisense protein (ASP) RNA transcripts in individuals infected with human immunodeficiency virus type 1 (HIV-1). Journal of General Virology, 2019, 100, 863-876.	1.3	15
50	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. Journal of Clinical Investigation, 2019, 129, 4769-4785.	3.9	27
51	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology, 2018, 92, .	1.5	46
52	Hyperglycaemia is inversely correlated with live M. bovis BCGâ€specific CD4⁺ T cell responses in Tanzanian adults with latent or active tuberculosis. Immunity, Inflammation and Disease, 2018, 6, 345-353.	1.3	7
53	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	1.5	10
54	Antibodies to Chlamydia trachomatis and reproductive health issues in women with SLE: a caseâ€“control study. Lupus Science and Medicine, 2018, 5, e000293.	1.1	0

#	Article	IF	Citations
55	Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial. Vaccine, 2018, 36, 6163-6169.	1.7	42
56	CD32 ⁺ and PD-1 ⁺ Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals. Journal of Virology, 2018, 92, .	1.5	38
57	TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. Journal of Clinical Investigation, 2018, 128, 4387-4396.	3.9	55
58	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Science Translational Medicine, 2017, 9, .	5.8	135
59	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. Journal of Virology, 2017, 91, .	1.5	29
60	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. Journal of Virology, 2017, 91, .	1.5	26
61	A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. Virology, 2017, 507, 242-256.	1.1	5
62	Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial. EBioMedicine, 2017, 24, 195-204.	2.7	12
63	Targeted Immune Interventions for an HIV-1 Cure. Trends in Molecular Medicine, 2017, 23, 945-961.	3.5	41
64	The Immunopathogenesis of HIV-1 Infection. , 2017, , 837-845.e3.		1
65	Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania. PLoS Neglected Tropical Diseases, 2017, 11, e0005817.	1.3	29
66	Therapeutic vaccines and immunological intervention in HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 576-584.	1.5	40
67	Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation. Human Immunology, 2016, 77, 483-489.	1.2	35
68	PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nature Medicine, 2016, 22, 754-761.	15.2	388
69	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Journal of Virology, 2016, 90, 4133-4149.	1.5	22
70	A case for preART-adjusted endpoints in HIV therapeutic vaccine trials. Vaccine, 2016, 34, 1282-1288.	1.7	11
71	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathogens, 2015, 11, e1005142.	2.1	445
72	COMPASS identifies T-cell subsets correlated with clinical outcomes. Nature Biotechnology, 2015, 33, 610-616.	9.4	232

#	Article	IF	Citations
73	NFÎºB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1333-E1342.	3.3	26
74	Interleukin-1- and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins. Journal of Virology, 2015, 89, 3819-3832.	1.5	10
75	Emerging single-cell technologies in immunology. Journal of Leukocyte Biology, 2015, 98, 23-32.	1.5	19
76	Combined Use of Mycobacterium tuberculosisâ€“Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. Clinical Infectious Diseases, 2015, 60, 432-437.	2.9	75
77	Immune correlates of vaccine protection against HIV-1 acquisition. Science Translational Medicine, 2015, 7, 310rv7.	5.8	179
78	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. Journal of Virology, 2015, 89, 8643-8650.	1.5	42
79	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, 2015, 89, 8525-8539.	1.5	35
80	Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. Journal of Virology, 2015, 89, 970-988.	1.5	30
81	Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. Journal of Experimental Medicine, 2014, 211, 2033-2045.	4.2	108
82	Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 Î±-chain (CD11a) in MS patients. Multiple Sclerosis Journal, 2014, 20, 837-842.	1.4	15
83	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4Ã—: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2014, 14, 291-300.	4.6	100
84	Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. Journal of Experimental Medicine, 2013, 210, 143-156.	4.2	581
85	Mycobacterium tuberculosisâ€specific CD8⁺ T cells are functionally and phenotypically different between latent infection and active disease. European Journal of Immunology, 2013, 43, 1568-1577.	1.6	172
86	MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects. Neurological Sciences, 2013, 34, 539-543.	0.9	4
87	Immune response to HIV. Current Opinion in HIV and AIDS, 2013, 8, 1.	1.5	43
88	Vaccine and immunotherapeutic interventions. Current Opinion in HIV and AIDS, 2013, 8, 236-242.	1.5	21
89	Systems biology in the development of HIV vaccines. Current Opinion in HIV and AIDS, 2012, 7, 44-49.	1.5	2
90	The Number of Toll-Like Receptor 9-Agonist Motifs in the Adenovirus Genome Correlates with Induction of Dendritic Cell Maturation by Adenovirus Immune Complexes. Journal of Virology, 2012, 86, 6279-6285.	1.5	25

#	Article	IF	Citations
91	HLA-B7â€“Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis. Journal of Immunology, 2012, 188, 4671-4680.	0.4	36
92	Nonrandom Distribution of Cryptic Repeating Triplets of Purines and Pyrimidines (RNY)_nin gp120 of HIV Type1. AIDS Research and Human Retroviruses, 2012, 28, 493-504.	0.5	0
93	Functional Avidity: A Measure to Predict the Efficacy of Effector T Cells?. Clinical and Developmental Immunology, 2012, 2012, 1-14.	3.3	101
94	NYVAC immunization induces polyfunctional HIVâ€specific Tâ€cell responses in chronicallyâ€infected, ARTâ€treated HIV patients. European Journal of Immunology, 2012, 42, 3038-3048.	1.6	30
95	Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTUÂ®-Multi-HIVB, in untreated HIV-1 infected subjects. Vaccine, 2012, 30, 4046-4054.	1.7	36
96	Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. PLoS ONE, 2012, 7, e35485.	1.1	30
97	Modulation of human memory Tâ€cell function by different antigenâ€presenting cells. European Journal of Immunology, 2012, 42, 799-802.	1.6	3
98	Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens. PLoS ONE, 2012, 7, e48524.	1.1	30
99	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine, 2011, 29, 8309-8316.	1.7	70
100	Dominant TNF-Î±+ Mycobacterium tuberculosisâ€specific CD4+ T cell responses discriminate between latent infection and active disease. Nature Medicine, 2011, 17, 372-376.	15.2	380
101	Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7131-7136.	3.3	121
102	DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa. Journal of Virology, 2011, 85, 9854-9862.	1.5	35
103	Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors. PLoS ONE, 2011, 6, e18164.	1.1	46
104	Poxvirus vector-based HIV vaccines. Current Opinion in HIV and AIDS, 2010, 5, 391-396.	1.5	68
105	Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurology, The, 2010, 9, 264-272.	4.9	86
106	Cytokine mRNA profile of Epsteinâ€“Barr virus-stimulated highly differentiated T cells in multiple sclerosis: A pilot study. Journal of Neuroimmunology, 2010, 225, 167-170.	1.1	4
107	Long sequence duplications, repeats, and palindromes in HIV-1 gp120: Length variation in V4 as the product of misalignment mechanism. Virology, 2010, 399, 167-175.	1.1	12
108	Intrathecal immune responses to EBV in early MS. European Journal of Immunology, 2010, 40, 878-887.	1.6	83

#	Article	IF	Citations
109	Proliferation Capacity and Cytotoxic Activity Are Mediated by Functionally and Phenotypically Distinct Virus-Specific CD8 T Cells Defined by Interleukin-7Rî± (CD127) and Perforin Expression. Journal of Virology, 2010, 84, 3868-3878.	1.5	46
110	The immunopathogenesis of HIV-1 infection. , 2010, , 944-953.		0
111	The Polymorphic Nature of HIV Type 1envV4 Affects the Patterns of Potential N-Glycosylation Sites in Proviral DNA at the Intrahost Level. AIDS Research and Human Retroviruses, 2009, 25, 199-206.	0.5	10
112	Distinct Profiles of Cytotoxic Granules in Memory CD8 T Cells Correlate with Function, Differentiation Stage, and Antigen Exposure. Journal of Virology, 2009, 83, 2862-2871.	1.5	104
113	IL-2â€“ and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. Journal of Allergy and Clinical Immunology, 2009, 123, 758-762.	1.5	211
114	Polyfunctional HCVâ€specific Tâ€cell responses are associated with effective control of HCV replication. European Journal of Immunology, 2008, 38, 2665-2677.	1.6	138
115	EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine, 2008, 26, 3162-3174.	1.7	89
116	EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine, 2008, 26, 3153-3161.	1.7	54
117	A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response. Vaccine, 2008, 26, 4006-4014.	1.7	17
118	HIVâ€1â€Specific Immune Response. Advances in Pharmacology, 2008, 56, 75-92.	1.2	10
119	Activation of a dendritic cellâ€“T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. Journal of Experimental Medicine, 2008, 205, 2717-2725.	4.2	153
120	Independent Evolution of Hypervariable Regions of HIV-1 gp120: V4 as a Swarm of N-Linked Glycosylation Variants. AIDS Research and Human Retroviruses, 2008, 24, 106-113.	0.5	17
121	An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. Journal of Experimental Medicine, 2008, 205, 63-77.	4.2	273
122	Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain, 2008, 131, 1712-1721.	3.7	150
123	Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16233-16238.	3.3	118
124	Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure. Aids, 2007, 21, 23-30.	1.0	20
125	Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine, 2007, 25, 2120-2127.	1.7	96
126	Functional and phenotypic characterizationof tetanus toxoid-specific human CD4+ T cellsfollowing re-immunization. European Journal of Immunology, 2007, 37, 1129-1138.	1.6	39

#	Article	IF	Citations
127	Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response. Journal of Neuroimmunology, 2007, 192, 192-197.	1.1	7
128	Three-Year Immune Reconstitution in PI-Sparing and PI-Containing Antiretroviral Regimens in Advanced HIV-1 Disease. Antiviral Therapy, 2007, 12, 553-558.	0.6	6
129	Clinical studies of experimental vaccines. Current Opinion in HIV and AIDS, 2006, 1, 286-293.	1.5	4
130	Functional signatures of protective antiviral Tâ€cell immunity in human virus infections. Immunological Reviews, 2006, 211, 236-254.	2.8	256
131	Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nature Reviews Immunology, 2006, 6, 417-423.	10.6	190
132	Standardization of cytokine flow cytometry assays. BMC Immunology, 2005, 6, 13.	0.9	203
133	Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. European Journal of Immunology, 2005, 35, 3493-3504.	1.6	57
134	Understanding what makes a goodversus a bad vaccine. European Journal of Immunology, 2005, 35, 2528-2531.	1.6	2
135	HIV-1-specific IFN-Â/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7239-7244.	3.3	277
136	Functional Heterogeneity of Memory CD4 T Cell Responses in Different Conditions of Antigen Exposure and Persistence. Journal of Immunology, 2005, 174, 1037-1045.	0.4	271
137	Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nature Medicine, 2004, 10, 806-810.	15.2	426
138	Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. European Journal of Immunology, 2004, 34, 3525-3533.	1.6	169
139	Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1â€"infected subjects with progressive disease: changes after antiretroviral therapy. Blood, 2004, 103, 966-972.	0.6	345
140	Analysis of HIV-1â€" â€‰and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Blood, 2002, 100, 1381-1387.	0.6	97
141	Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. European Journal of Immunology, 2002, 32, 3756-3764.	1.6	79
142	Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature, 2001, 410, 106-111.	13.7	910
143	Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. Aids, 2000, 14, 2257-2263.	1.0	38
144	Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. Aids, 2000, 14, 1887-1897.	1.0	64

#	Article	IF	Citations
145	Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nature Medicine, 2000, 6, 762-768.	15.2	192
146	The moving target: mechanisms of HIV persistence during primary infection. Trends in Immunology, 1999, 20, 446-450.	7.5	48
147	Unraveling the strands of HIV's web. Nature Medicine, 1999, 5, 27-28.	15.2	16
148	Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope. European Journal of Immunology, 1999, 29, 3629-3635.	1.6	38
149	Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. Aids, 1999, 13, 1503-1509.	1.0	13
150	CCR2 Polymorphism and HIV Disease. Nature Medicine, 1998, 4, 252-253.	15.2	63
151	Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy. Nature Medicine, 1998, 4, 341-345.	15.2	129
152	Limited CD4+ T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy. Nature Medicine, 1998, 4, 794-801.	15.2	151
153	Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Longâ€Termâ€Nonprogressive Infection. Journal of Infectious Diseases, 1997, 176, 924-932.	1.9	311
154	Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. European Journal of Immunology, 1997, 27, 3166-3173.	1.6	43
155	The multi-faceted personality of HIV. Nature Medicine, 1997, 3, 1318-1320.	15.2	10
156	Introduction: Recent advances in the pathogenesis of human immunodeficiency virus infection. Seminars in Immunopathology, 1997, 18, 253-256.	4.0	3
157	Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 332, 209-216.	13.9	717
158	HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature, 1993, 362, 355-358.	13.7	1,837
159	The Immunopathogenesis of Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1993, 328, 327-335.	13.9	1,049
160	A Highly Potent Antibody Effective Against SARS-CoV-2 Variants of Concern. SSRN Electronic Journal, 0, , .	0.4	2
161	Case Report: SARS-CoV-2 as an unexpected causal agent of predominant febrile hepatitis. F1000Research, 0, 10, 400.	0.8	1